图片来源：中证指数官网，以上仅为对指数成分股列示，非个股推荐。 Wind数据显示，2025年6月30日芯片板块全天活跃，截至14:10，思特威上涨6.01%，芯原股份上涨5.42%，安集科技上涨4.66%，翱捷科技，寒武纪等个股跟 涨。 相关基金方面，天弘中证芯片产业ETF发起联接(A：012552；C：012553)与芯片ETF天弘(159310)紧密挂钩。该指数跟踪中证芯片产业指数，聚焦A股芯片全 产业链，选取业务涵盖芯片设计、制造、封装测试，以及提供半导体材料、晶圆设备、封装设备等关键环节的50家龙头企业作为成份股，全面反映中国芯片 产业上市公司的整体表现。 中证指数官网数据显示，截至6月27日，该指数前十大成份股包括中芯国际、北方华创、海光信息、寒武纪、豪威集团等，前十大成份股权重合计占比达 54.62%。 | 三三 中证指数 首页 产品与服务 三 | 研究与洞见 | 国际合作 | 信息披露 | 关于我们 | | --- | --- | --- | --- | --- | | CHINA SECURITIES INDEX | | | | | | 证券代码 | 证券名称 | 中证—级行业分类 | 中证二 ...

Revenue Performance - The footwear business generated revenue of approximately HKD 100.7 million, a 62.5% increase compared to approximately HKD 62 million in the same period last year, accounting for about 97% of total revenue[6]. - For the six months ended June 30, 2023, total revenue was HKD 104,131,000, with external sales from footwear products contributing HKD 100,660,000 and online medical services contributing HKD 102,000[67]. - The group achieved a profit of approximately HKD 3,400,000 in the first half of 2023, a 240% increase compared to the same period last year, primarily driven by consulting revenue of about HKD 1,700,000 and investment management revenue of approximately HKD 900,000[136]. - The financial services segment reported revenue of approximately HKD 3,400,000, a significant increase from HKD 1,000,000 in the same period of 2022, attributed to improved economic conditions and increased demand for consulting and investment management services[145]. - The revenue from the mainland China market was HKD 104,131,000, significantly higher than the HKD 63,516,000 reported in the previous year, indicating a strong market performance[197]. - The total revenue from the Macau market was HKD 8,968,000, compared to HKD 4,859,000 in the same period last year, showing an increase of 84.5%[197]. Sales and Growth - Same-store sales rose by approximately 54.3%, compared to a decline of 2.6% in the same period last year[6]. - The footwear business sales increased by 65.5% in the first half of 2023, with expectations for continued growth in the second half[11]. - Sales of footwear products reached HKD 100,660,000, significantly up from HKD 61,951,000 in the previous year[189]. - Retail sales accounted for HKD 98,466,000, an increase from HKD 60,208,000 in the prior year[189]. - The group plans to focus on developing financing consulting services and exploring new market opportunities, such as Singapore, in the second half of 2023[140]. Financial Performance - Gross profit for the period was approximately HKD 85.2 million, a 62.2% increase from approximately HKD 52.5 million in the same period last year, with a gross margin of approximately 81.9%[22]. - The company reported a total segment loss of HKD 6,048,000, with the footwear segment loss at HKD 1,254,000 and online medical services loss at HKD 4,457,000[67]. - The company incurred a pre-tax loss of HKD 14,290,000 for the six months ended June 30, 2023, compared to a profit of HKD 20,169,000 for the same period in 2022[78]. - The company reported a loss before tax of HKD 14,290,000 for the six months ended June 30, 2023, compared to a profit of HKD 16,706,000 in the same period last year[175]. - The company reported a loss attributable to shareholders of HKD 12,327,000 for the first half of 2023, compared to a profit of HKD 20,169,000 in the prior year, indicating a significant decline in profitability[129]. Cost and Expenses - Employee costs for the period were approximately HKD 39.1 million, accounting for about 37.6% of revenue, down from 60.1% in the same period last year[23]. - Administrative expenses increased by approximately HKD 22,000,000 compared to the same period in 2022, primarily due to rising medical expenses and director salaries in the footwear business[134]. - The group’s sales cost for the reporting period was approximately HKD 19,000,000, accounting for about 18.1% of revenue, compared to HKD 11,000,000 and 17.3% in the same period of 2022[148]. Assets and Liabilities - As of June 30, 2023, the group's debt-to-equity ratio was approximately 356.3%, a significant increase from 102.6% on December 31, 2022, primarily due to increased current liabilities of approximately HKD 20 million[28]. - The group's current liabilities exceeded current assets by approximately HKD 63,999,000 as of June 30, 2023, compared to HKD 48,415,000 as of December 31, 2022[58]. - The total assets as of June 30, 2023, amounted to HKD 187,227,000, an increase from HKD 176,052,000 as of December 31, 2022[70]. - The total liabilities increased to HKD 180,569,000 from HKD 157,115,000, with segment liabilities for footwear at HKD 87,110,000 and online medical services at HKD 27,177,000[70]. - The net asset value decreased to HKD 6,658,000 as of June 30, 2023, from HKD 18,937,000 as of December 31, 2022[178]. Operational Insights - The total number of registered users for the internet hospital reached 114,297, with approximately 17,080 online consultation orders received[9]. - The healthcare business reported zero revenue during the period, down from HKD 200,000 in the same period last year, due to operational suspension[134]. - The group has identified potential business development opportunities and acquisition targets in the healthcare sector, with a focus on high-growth investment goals[35]. - The group decided to pause the development of its Australian healthcare business due to market instability and funding concerns, while seeking financing to continue promoting high-margin natural health products[12]. Management and Governance - The group has not declared an interim dividend for the reporting period, consistent with the previous year[38]. - The company is actively seeking suitable candidates to fill vacancies in the board and committees to comply with listing rules[173]. - The company has not held its annual general meeting within the required timeframe, constituting a breach of listing rules[171]. - The board is committed to ensuring financial resources are utilized in a cost-effective manner to fulfill the group's financial responsibilities[29].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA健康國際控股有限公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 截至二零二三年六月三十日止六個月的 中期業績公告 財務摘要 截至六月三十日止六個月 二零二三年 二零二二年 | --- | --- | --- | --- | |---------------------------------|--------|----------|--------| | 收入 | 千港元 | 104,131 | 63,516 | | 毛利 | 千港元 | 85,233 | 52,549 | | 除稅前（虧損）╱溢利 | 千港元 | (14,290) | 16,706 | | 本公司擁有人應佔（虧損）╱溢利 | 千港元 | (12,327) | 20,169 | | 毛利率 | % | 81.9 | 82.7 ...

Financial Performance - The company's revenue for the year ended December 31, 2022, was approximately HKD 144.6 million, a decrease of about 10.1% compared to HKD 160.9 million in 2021[22]. - Gross profit for the same period was HKD 113.9 million, resulting in a gross margin of 78.8%, up from 65.1% in the previous year[22]. - The company reported a profit attributable to shareholders of HKD 9.6 million, a significant recovery from a loss of HKD 60.8 million in 2021[22]. - The group's revenue for the year was approximately HKD 144.6 million, a decrease of about 10.1% compared to approximately HKD 160.9 million in the previous year, primarily due to a decline in footwear business revenue[36]. - Footwear business revenue for the year was approximately HKD 141.4 million, down about 7.5% from approximately HKD 152.9 million in the previous year, attributed to a significant decline in foot traffic and consumer spending due to tightened pandemic measures[30]. - The health supplement segment generated revenue of approximately HKD 200,000, a decrease of about 88.2% from approximately HKD 1.7 million in the previous year, mainly due to ongoing COVID-19 outbreaks in Australia[40]. - Online medical services recorded revenue of approximately HKD 400,000, down from approximately HKD 800,000 in the previous year, reflecting the continued low revenue impact from the pandemic[32]. - The financial services segment's revenue was approximately HKD 2.5 million, a decrease of about 55.4% from approximately HKD 5.6 million in the previous year, primarily due to reduced investment management and advisory service income[39]. - The total comprehensive loss for the year was HKD 3,101,000, down from HKD 6,743,000 in 2021, indicating a 54% reduction in losses[178]. Liquidity and Financial Health - The current ratio remains at 0.7, indicating a stable liquidity position[6]. - The total liabilities to equity ratio improved to 102.6% from 311.8% in the previous year, reflecting better financial health[6]. - The asset-to-equity ratio improved to approximately 102.6% from about 311.8% in the previous year, mainly due to a decrease in other borrowings and bank loans[49]. - As of December 31, 2022, the group's cash and bank balances were approximately HKD 33.6 million, an increase of about 25.8% from approximately HKD 26.7 million at the end of the previous year[47]. - As of December 31, 2022, the company had a current liability exceeding its current assets by approximately HKD 48,415,000, raising significant doubts about its ability to continue as a going concern[73]. - The company reported a net cash outflow from operating activities of HKD 2,781,000 in 2022, compared to HKD 3,051,000 in 2021, showing an improvement of 8.9%[179]. - The company reported a net cash outflow of HKD 3,222,000 in 2022, slightly higher than HKD 3,034,000 in 2021[179]. Business Strategy and Market Expansion - The company plans to expand its market presence in Singapore and Australia while implementing cost control measures[10][13]. - The company aims to consolidate its business segments and seek strategic partnerships in the health industry to create sustainable value for shareholders[18]. - The company plans to allocate 30% of its funds, approximately HKD 22,349,100, to enhance the supply chain and develop new products in the Australian health supplement sector[69]. - TATA Health will continue to seek strategic partnerships in the health industry to build a healthy business ecosystem[87]. - The company aims to improve its one-stop internet hospital platform, focusing on customer service support and product development[69]. - The online healthcare service business is in the final stages of its initial phase, with plans to strengthen marketing efforts and expand sales performance after establishing a one-stop internet medical platform[60]. Employee and Training Initiatives - The company employed 156 staff members as of December 31, 2022, down from 185 in the previous year, and conducted various training activities to improve service quality[70]. - The total training hours during the reporting period amounted to approximately 1,399 hours, a significant increase from 623 hours in the previous year[152]. - The average training hours per employee are 14.0 hours for females and 25.0 hours for males, indicating a disparity in training engagement[154]. - The company invests in employee development and training, recognizing human capital as a critical component of its ongoing success[161]. - Employee turnover rate by gender shows 19% for males and 81% for females, with a total turnover rate of 22% in China, 3% in Australia, and 75% in Hong Kong[150]. Environmental, Social, and Governance (ESG) Efforts - TATA Health aims to enhance shareholder, customer, and community value through high-quality products and services while focusing on sustainable development[75]. - The group is committed to maintaining good corporate governance standards and reducing greenhouse gas emissions, energy consumption, and protecting natural resources[75]. - The company has identified key environmental, social, and governance (ESG) issues through stakeholder engagement and materiality assessments[84]. - The company has established an ESG task force to enhance employee awareness of environmental protection and social responsibility[78]. - The company monitors various key performance indicators related to ESG matters to assess the effectiveness of its policies and management systems[78]. - The company has implemented various environmental measures in its workplaces, including the use of LED lighting to reduce energy consumption[111]. - The company is gradually adopting electronic work platforms to move towards a paperless workplace[108]. - The company actively encourages employees to reduce printing and use double-sided printing for internal documents[108]. - The company has reduced greenhouse gas emissions intensity by approximately 34.61% during the reporting period[109]. - The company achieved a reduction in electricity consumption to 244,320 kWh in 2022 from 333,955 kWh in 2021, marking a decrease of about 26.8%[139]. - The company maintained a relatively low water consumption during the reporting period, with total water usage remaining stable at approximately 0.1 tons, consistent with the previous year[143]. - Over 90% of the leather used in the company's shoe products is sourced from suppliers certified by the Leather Working Group, ensuring environmental protection standards[144]. - The company encourages the use of eco-friendly materials, with 95% of the packaging for its Clarks brand shoes made from environmentally friendly materials[142]. - The company aims to continuously monitor and reduce non-hazardous waste generation annually[134]. - The company has not encountered any significant environmental law violations during the reporting period in Hong Kong and Australia[134]. Corporate Governance and Compliance - The company is committed to adhering to labor standards, prohibiting child and forced labor, and regularly reviewing employee data to ensure compliance[154]. - The company has implemented internal guidelines and reporting systems regarding occupational health and safety, ensuring a high standard of hygiene and safety in retail environments[151]. - There were no product recalls due to safety and health reasons during the reporting period, and the company received zero complaints related to products or services[157]. - The company has not reported any serious or fatal workplace injuries over the past three years, indicating a strong health and safety record[166]. - The company has developed emergency plans to address extreme weather conditions, ensuring continuity of operations during adverse events[160]. - The company has no significant related party transactions that require disclosure under the listing rules for the year[194]. - There were no major post-balance sheet events affecting the group since the end of the financial year[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA健康國際控股有限公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 截至二零二二年十二月三十一日止年度的 全年業績公告 財務摘要 二零二二年 二零二一年 | --- | --- | --- | --- | |---------------------------------|--------|---------|----------| | 收入 | 千港元 | 144,606 | 160,925 | | 毛利 | 千港元 | 113,944 | 104,718 | | 除稅前溢利╱（虧損） | 千港元 | 4,104 | (69,143) | | 本公司擁有人應佔溢利╱（虧損） | 千港元 | 9,613 | (60,761) | | 毛利率 | % | 78.8 | 65.1 | | 本公司擁有 ...

Revenue Performance - Revenue for the six months ended June 30, 2022, was approximately HKD 63,516,000, a decrease of 12.6% compared to HKD 73,116,000 in the same period of 2021[8]. - The total revenue for the group during the reporting period was approximately HKD 63,500,000, down about 13.1% from HKD 73,100,000 in the same period last year[28]. - For the six months ended June 30, 2022, total revenue was HKD 63,516,000, a decrease of 13.1% compared to HKD 73,116,000 for the same period in 2021[98]. - Revenue from Hong Kong was HKD 58,056,000, down from HKD 66,662,000 in the previous year, representing a decline of 12.4%[106]. Profitability - The company reported a profit attributable to owners of the company of HKD 20,169,000, compared to a loss of HKD 27,083,000 in the same period last year[8]. - The gross profit for the group was approximately HKD 52,500,000, an increase of about 19.0% from HKD 44,100,000 year-on-year, resulting in a gross margin of approximately 82.7%[36]. - The company achieved a profit before tax of HKD 16,706,000, a significant recovery from a loss of HKD 31,654,000 in the prior year[71]. - The group reported a pre-tax profit of HKD 20,169,000 for the six months ended June 30, 2022, compared to a loss of HKD 27,083,000 for the same period in 2021[118]. - Total comprehensive income for the period was HKD 19,266,000, compared to a loss of HKD 31,455,000 in the previous year[71]. Segment Performance - The footwear business generated revenue of approximately HKD 61,951,000, a decline of 7.3% year-on-year, with same-store sales down by 2.6%[12][15]. - The healthcare segment recorded revenue of approximately HKD 200,000, down from HKD 600,000 in the same period of 2021 due to COVID-19 lockdowns in Australia[16]. - The financial services segment achieved revenue of approximately HKD 964,000, significantly lower than HKD 4,300,000 in the previous year, resulting in a net loss of HKD 1,800,000[18]. - The online medical services segment reported revenue of approximately HKD 400,000, a decrease of about 71.4% compared to HKD 1,400,000 in the same period last year, with a segment loss of HKD 5,000,000[19]. - The revenue breakdown includes sales of footwear products at HKD 61,951,000, health products at HKD 222,000, financial services at HKD 964,000, and online medical services at HKD 379,000[103]. Financial Position - The current liquidity ratio improved to 0.8 from 0.7, while the debt ratio decreased significantly to 116.1% from 311.8%[7]. - As of June 30, 2022, the group's bank deposits and cash amounted to approximately HKD 24,300,000, a decrease of about 8.9% from HKD 26,700,000 on December 31, 2021[41]. - The group's debt ratio as of June 30, 2022, was approximately 116.1%, a significant decrease from 311.8% on December 31, 2021, due to an increase in net assets and a reduction in current liabilities by approximately HKD 23,400,000[45]. - The total liabilities exceeded current assets by approximately HKD 26,781,000 as of June 30, 2022, an improvement from HKD 38,004,000 as of December 31, 2021[90]. - The total reported liabilities increased to HKD 146,517,000 as of June 30, 2022, compared to HKD 163,256,000 as of December 31, 2021, showing a decrease of 10.2%[108]. Operational Efficiency - Employee costs were approximately HKD 38,200,000, accounting for about 60.1% of revenue, compared to 55.8% in the same period last year[37]. - The average inventory turnover period increased to 346.9 days from 215.4 days, indicating potential inventory management challenges[7]. - The group incurred a net foreign exchange loss of HKD 1,077,000 and recognized a gain from property sales of HKD 32,959,000 during the reporting period[111]. - The group recognized a reversal of inventory provision amounting to HKD 13,162,000, which positively impacted the cost of sales[111]. - The company aims to enhance its operational efficiency and explore new strategies for market expansion[92]. Future Plans - The company plans to increase investment in the healthcare segment and strengthen partnerships with Australian natural health brands to develop high-margin products[12]. - The company aims to expand its presence in the health industry and identify new business development opportunities and acquisition targets[12]. - The group plans to expand its customer base in the footwear business while maintaining stable revenue in the second half of 2022[20]. - The online medical services division is transitioning to a post-startup phase, with plans to increase marketing efforts and expand sales performance[24]. - The company is considering the sale of existing properties and other assets to improve liquidity if appropriate[92]. Shareholder Information - The company’s major shareholder, Mr. Yang Jun, holds 61.77% of the issued share capital, amounting to 149,993,617 shares[14]. - Major shareholder TATA Health holds 149,993,617 shares, representing 61.77% of the company's issued share capital as of June 30, 2022[144]. - Great Wall International Investment X Limited holds 123,993,617 shares, accounting for 51.06% of the issued share capital, with these shares pledged to guarantee loans[145]. - The average number of ordinary shares weighted for the period was 242,845,000, compared to 221,012,044 shares in the previous year, reflecting an increase of 9.9%[118]. - The total number of issued and fully paid ordinary shares increased to 242,845,000 as of June 30, 2022, from 214,000,000 on January 1, 2021, due to a placement of 28,845,000 shares[13].

Financial Performance - The company's revenue for the year ended December 31, 2021, was HKD 160.93 million, representing a 3.5% increase compared to HKD 155.36 million in 2020[9]. - The gross profit for the same period was HKD 104.72 million, with a gross margin of 65.1%, significantly up from 22.1% in the previous year[9][15]. - The company reported a pre-tax loss of HKD 69.14 million, an improvement from a loss of HKD 172.68 million in 2020[9]. - Total revenue for the group was HKD 160,900,000, an increase of about 3.5% from HKD 155,400,000 in 2020, driven by a rise in footwear business revenue[29]. - The group reported a pre-tax loss of HKD 69,100,000 for the year, an improvement from a pre-tax loss of HKD 172,700,000 in the previous year[40]. Business Segments - The footwear business generated revenue of approximately HKD 152.9 million, an increase of 18.8% from HKD 128.7 million in 2020, with same-store sales rising by 23.6%[18]. - The health products segment recorded revenue of approximately HKD 1.7 million, significantly impacted by travel restrictions due to the pandemic[15]. - The financial services segment saw a decline in revenue to approximately HKD 5.6 million compared to the previous year[16]. - The healthcare segment reported revenue of approximately HKD 1,700,000, a decrease of about 69% compared to HKD 5,500,000 in 2020, primarily due to ongoing COVID-19 outbreaks in Australia[32]. - The financial services segment generated revenue of HKD 5,600,000, down approximately 72.6% from HKD 20,300,000 in 2020, mainly due to a reduction in asset management fees[31]. User Engagement and Online Services - The company has registered approximately 140,000 users and patients on its one-stop internet medical platform, with revenue of about HKD 0.8 million for the year[16]. - The total number of registered users for the online medical services reached approximately 135,000, with around 16,500 online consultation orders received[24]. - TATA Health continues to expand its online medical services, including the establishment of the "Shanghai Fever Consultation Platform" in collaboration with Xuhui District Central Hospital[74]. Financial Ratios and Stability - The current ratio decreased to 0.7 times from 1.2 times in the previous year, indicating a decline in liquidity[10]. - The debt-to-equity ratio improved to 311.8% from 722.5% in 2020, reflecting better financial stability[10]. - The group's debt-to-equity ratio improved to approximately 311.8% as of December 31, 2021, compared to 722.5% on December 31, 2020, due to an increase in non-current assets and a decrease in non-current liabilities of HKD 26,600,000 and HKD 35,800,000 respectively[43]. Investment and Future Plans - The company plans to continue investing in the health products sector despite the challenges, focusing on market expansion and cost control strategies[15][17]. - The group plans to invest approximately 30% of the net proceeds from a special placement into the healthcare sector, aiming to collaborate with undervalued brands and become exclusive distributors in the Chinese market[26]. - The group anticipates a strong recovery in retail sales in the second half of 2022, with an expected year-on-year increase of 7% due to government-issued consumption vouchers[25]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to reducing greenhouse gas emissions and energy consumption while providing a safe working environment for employees[74]. - TATA Health aims to enhance its environmental, social, and governance (ESG) performance through stakeholder engagement and materiality assessments conducted annually[77]. - The company has established an ESG task force to monitor significant issues and evaluate the effectiveness of implemented policies[85]. - The company has implemented various environmental measures, including the use of LED lighting and the installation of variable frequency air conditioning systems to enhance energy efficiency[106]. - The company has committed to reducing water usage and promoting water conservation awareness among employees, maintaining relatively low water consumption levels[109]. Employee and Labor Practices - The company employed a total of 185 employees as of December 31, 2021, with 129 in footwear, 10 in financial services, and 46 in healthcare[121]. - Employee distribution shows 67% female and 33% male, with 93.8% full-time and 6.2% part-time[124]. - The total training hours for employees in the current year amounted to approximately 623 hours, a decrease from 1,364 hours in the previous year[140]. - There were no reported employee injuries leading to lost days over the past three years, indicating a strong focus on occupational health and safety[136]. - The company emphasizes employee mental health by organizing activities to strengthen team spirit and promote work-life balance[137]. Corporate Governance - The company has a strong board with members holding qualifications from various prestigious institutions, enhancing its governance and oversight capabilities[172]. - The independent non-executive director, Mr. Xie Rongxing, has over 20 years of experience in accounting, law, and securities, contributing to the company's compliance and regulatory framework[172]. - The company is committed to maintaining high standards of corporate governance, as evidenced by the qualifications and experience of its board members[168]. - The board consists of 9 members, with 2 executive directors (22.2%), 4 non-executive directors (44.4%), and 3 independent non-executive directors (33.3%)[181]. - The company has adopted the corporate governance code since its listing on July 11, 2013, and has complied with the code throughout the year[178].

TATA Health International Holdings Limited TATA健康國際控股有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) ( 股份代號 : 1255) 目錄 公司資料 2 財務摘要 3 主席報告 4 管理層討論及分析 6 簡明綜合損益及其他全面收益表 17 簡明綜合財務狀況表 18 簡明綜合權益變動表 20 簡明綜合現金流量表 21 簡明綜合財務報表附註 22 一般資料 34 公司資料 董事會 執行董事 楊軍先生（主席） 賴文敬先生 非執行董事 林哲明先生 林鈞先生 朱俊豪先生 陳安華先生 獨立非執行董事 謝榮興先生 閻海峰教授 談玉英女士 審核委員會 謝榮興先生（主席） 閻海峰教授 談玉英女士 薪酬委員會 閻海峰教授（主席） 謝榮興先生 楊軍先生 提名委員會 楊軍先生（主席） 謝榮興先生 閻海峰教授 授權代表 賴文敬先生 黃天宇先生 公司秘書 黃天宇先生 註冊辦事處 Clifton House 75 Fort Street PO Box 1350 Grand Cayman KY1-1108 Cayman Islands 香港總辦事處及主要營業地點 香 ...

TATA Health International Holdings Limited TATA健康國際控股有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) ( 股份代號 : 1255) DSC FINANCE 屏安 O PLUS", STL-35", GINNER ATED aXs BRAIN INE GINNDO BILOBA aXs LIFE a){s MERE MERE MERE (1) Previouslate | --- | |--------------------------| | 目錄 | | | | 公司資料 | | 財務摘要 | | 主席報告 | | 管理層討論及分析 | | 環境、社會及管治報告 | | 董事及秘書 | | 企業管治報告 | | 董事會報告 | | 獨立核數師報告 | | 綜合損益及其他全面收益表 | | 綜合財務狀況表 | | 綜合權益變動表 | | 綜合現金流量表 | | 綜合財務報表附註 | | | 2 3 4 6 17 31 35 51 61 64 65 67 68 70 五年財務概要 132 -DRIVE 公司資料 | --- | --- ...

Financial Performance - Revenue for the first half of 2020 was HKD 79,099,000, a decrease of 58.8% compared to HKD 191,670,000 in the same period of 2019[9]. - Gross profit for the same period was HKD 11,130,000, down 90.3% from HKD 114,472,000 in 2019, resulting in a gross margin of 14.1%[9]. - The company reported a loss attributable to shareholders of HKD 85,243,000, compared to a loss of HKD 3,155,000 in 2019, reflecting a loss margin of (107.8%)[9]. - The total revenue of the group for the reporting period was approximately HKD 79,100,000, a decrease of 58.7% compared to HKD 191,700,000 in the same period of 2019[29]. - The gross profit for the reporting period was approximately HKD 11,100,000, a decrease of 90.3% compared to HKD 114,500,000 in the same period of 2019[36]. - The company reported a total loss attributable to owners of HKD 85,243,000, compared to a loss of HKD 3,155,000 in the previous year, underscoring the financial difficulties faced[75]. - The company reported a net cash inflow from operating activities of HKD 7,634,000 for the six months ended June 30, 2020, down from HKD 29,408,000 in the same period of 2019, representing a decrease of approximately 74%[90]. - The total comprehensive loss for the period was HKD 95,224,000, compared to a loss of HKD 2,976,000 in the prior year, highlighting ongoing challenges[75]. - Basic and diluted loss per share was HKD 0.398, a significant increase from HKD 0.015 in the same period last year[75]. Segment Performance - The footwear business generated revenue of approximately HKD 66,900,000, a decline of 56.4% from HKD 153,400,000 in the previous year[17]. - The health products segment reported revenue of HKD 3,800,000, significantly down from HKD 28,700,000 in 2019, with a segment loss of HKD 2,700,000[18]. - The financial services segment recorded revenue of approximately HKD 8,100,000 during the reporting period[13]. - The revenue from the footwear business was approximately HKD 66,900,000, down 56.4% from HKD 153,400,000 in the same period of 2019[30]. - The revenue from the financial services business was approximately HKD 8,100,000, slightly down from HKD 9,600,000 in the same period of 2019[31]. - The healthcare business generated revenue of approximately HKD 3,800,000, a significant decline from HKD 28,700,000 in the same period of 2019[32]. - The online medical services business recorded revenue of approximately HKD 300,000, as it only commenced operations in August 2019[33]. - The segment performance showed significant losses, with total segment loss before tax amounting to HKD 93,831,000 for the six months ended June 30, 2020[120]. Operational Metrics - Same-store sales experienced a decline of approximately 47.5% during the reporting period[17]. - The average trade receivables turnover period increased to 32.4 days from 23.0 days, while the average inventory turnover period was 286.1 days compared to 347.8 days in the previous period[9]. - The current ratio decreased to 1.5 times from 2.2 times, and the debt-to-equity ratio rose to 75.7% from 37.4%[9]. - Employee costs for the reporting period were approximately HKD 50,000,000, accounting for 63.3% of revenue, compared to 25.5% in the same period of 2019[37]. - The company experienced a foreign exchange loss of HKD 85,243,000 during the period, impacting overall financial results[90]. - The company noted a reduction in retail points due to the impact of COVID-19, which affected operational performance and revenue[94]. Investments and Future Plans - The company plans to continue investing in the health products segment, particularly in the cross-border e-commerce platform Zebra and collaboration with Australian health brand AXS[12]. - The company plans to expand its healthcare business from Australia to other markets to increase revenue and profit diversification[26]. - The company plans to inject a total of RMB 37,800,000 into Shangying Hospital, with ownership remaining at 52% for the company, 39.65% for Shangying Global, and 8.35% for Shanghai Xinran after the capital increase[59]. - There were no major investments or acquisitions during the reporting period, and no future plans for significant investments or acquisitions were noted[58]. Financial Position - As of June 30, 2020, the group's bank deposits and cash were approximately HKD 51,100,000, a 9.2% increase from HKD 46,800,000 on December 31, 2019[42]. - Non-current assets decreased to HKD 67,794,000 from HKD 100,946,000, indicating a reduction in the company's asset base[77]. - Current assets, including inventory, dropped to HKD 157,181,000 from HKD 218,506,000, reflecting a decline in liquidity[77]. - The company's net current liabilities increased, resulting in a net current asset value of HKD 54,253,000, down from HKD 117,926,000[77]. - Total equity attributable to owners of the company decreased to HKD 75,626,000 from HKD 160,629,000, indicating a significant reduction in shareholder value[80]. - The company’s total equity as of June 30, 2020, was HKD 85,342,000, down from HKD 236,916,000 as of January 1, 2019, indicating a significant reduction in shareholder equity[90]. - The company’s total liabilities decreased to HKD 139,633,000 as of June 30, 2020, from HKD 146,925,000 as of December 31, 2019[126]. Governance and Compliance - The board has resolved not to declare an interim dividend for the reporting period, consistent with the previous year[67]. - The company is undergoing a name change from "S. Culture International Holdings Limited" to "TATA Health International Holdings Limited," which was approved by shareholders on June 18, 2020[63]. - The company has not reported any significant issues that would affect the preparation of its financial statements according to Hong Kong Accounting Standards[72]. - The company’s financial statements are subject to review under Hong Kong Accounting Standards, ensuring compliance with relevant regulations[70]. - The board has reviewed the company's corporate governance practices and confirmed compliance with the corporate governance code as per the listing rules[182]. - The number of independent non-executive directors was below the required minimum during the reporting period, but compliance was restored after appointing two new independent directors[185]. - The audit committee, composed of three independent non-executive directors, reviewed the group's key accounting policies and discussed risk management and financial reporting matters[188]. Employee and Shareholder Information - As of June 30, 2020, the group employed approximately 249 employees, a decrease from 257 employees as of December 31, 2019[66]. - The total compensation for key management personnel increased to HKD 4,367,000 for the six months ended June 30, 2020, compared to HKD 3,032,000 for the same period in 2019, representing a growth of 44.1%[16]. - Mr. Yang Jun holds 149,993,617 shares, accounting for 70.09% of the company's issued share capital as of June 30, 2020[160]. - The company has a significant shareholder, Great Wall International Investment X Limited, which holds 119,993,617 shares, representing 56.07% of the issued share capital[171]. - The proposed transfer of 42,800,000 shares to 商贏投資 is still pending completion as of June 30, 2020[161]. - The company’s major shareholders include 商贏金融 and 商贏環球, both holding substantial stakes of 70.09% and 20.00% respectively[171].